Related and Nonrelated Parties [Axis] Related Party [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] IPO [Member] Over-Allotment Option [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Underwriting Agreement [Member] Securities Purchase Agreement [Member] Investor [Member] Measurement Input Type [Axis] Weight Average Cost Capital [Member] Statistical Measurement [Axis] Minimum [Member] Measurement Input, Risk Free Interest Rate [Member] Maximum [Member] Measurement Input, Expected Term [Member] License Agreement [Member] Service Agreement [Member] Services Agreement [Member] Non Recurring Research Arrangement [Member] Legal Entity [Axis] Aptar Technology [Member] Award Type [Axis] Nasus Pharmas Intranasal Naloxone Powder Spray [Member] Nasus Pharmas Intranasal Epinephrine Powder Candidate [Member] Settlement Agreement [Member] New Master Service Agreement [Member] New Aptar Agreement [Member] Supply Agreement [Member] Consulting Agreement [Member] Segments [Axis] Single Reportable Segment [Member] Antidilutive Securities [Axis] Share Options [Member] Ordinary Warrants [Member] Underwriter Warrants [Member] 2024 SAFE [Member] Mr Udi Gilboa [Member] Dr. Dalia Meggido [Member] Dr Ronnie Hershman [Member] Mr. Ehud Gilboa [Member] Mr. Ehud Gilboa and Dr. Dalia Meggido [Member] Udi Gilboa [Member] 2024 SAFEs [Member] Title and Position [Axis] Chief Executive Officer [Member] Director [Member] Class of Stock [Axis] Common Class A [Member] Plan Name [Axis] 2019 Plan [Member] Sub Plan [Member] Non-executive Directors [Member] Chief Financial Officer [Member] Officer [Member] Mr.Dan Teleman [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Vesting [Axis] Share-Based Payment Arrangement, Tranche One [Member] Share-Based Payment Arrangement, Tranche Two [Member] Share-Based Payment Arrangement, Tranche Three [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Asset Current assets Cash and cash equivalents Restricted cash Short-term deposit Prepaid expenses and other current assets Total current assets Right-of-use assets Property and equipment, net Total Assets Liabilities and Shareholders’ Equity Current liabilities: Accounts payable Accrued expense and other current liabilities (of which $94 and $136 are to related parties as of June 30, 2026 and December 31, 2025, respectively) Current operating lease liabilities Current liabilities related to discontinued operations Total current liabilities Noncurrent operating lease liabilities Total Liabilities Commitments and contingencies (see Note 5 ) Shareholders’ equity Ordinary Shares, no par value; 50,000,000 shares authorized. 11,710,808 and 9,015,383 shares issued as of June 30,2026 and December 31, 2025, respectively. Additional paid-in capital Accumulated deficit Total Shareholders’ Equity Total Liabilities and Shareholders’ Equity Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Accrued expense and other current liabilities Ordinary shares, par value Ordinary shares, shares authorized Ordinary shares, shares issued Income Statement [Abstract] Operating expenses: Research and development (of which $320 and $295 are with related parties in 2026 and 2025, respectively) General and administrative (of which $839 and $286 are with related parties in 2026 and 2025, respectively) Total operating expenses Operating loss from continuing operations Change in fair value of convertible securities Interest income Other expenses, net Loss from continuing operations Net income (loss) from discontinued operations Net loss Loss per share attributable to shareholders: Basic Diluted Weighted average Ordinary Shares outstanding – basic Weighted average Ordinary Shares outstanding – diluted Research and development General and administrative Statement [Table] Statement [Line Items] Beginning Balance Balance, shares Issuance of Ordinary Shares and Ordinary Warrants in a private placement (see Note 1d) Issuance of Ordinary Shares and Ordinary Warrants in a private placement (see Note 1d), shraes Shared based compensation Net loss Ending Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Less: Net loss (income) from discontinued operations Loss from continuing operations Adjustments to reconcile loss from continuing operations to net cash used in operating activities: Share-based compensation Change in fair value of convertible securities Effect of exchange rates Change in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable Non- cash lease expense Operating lease liabilities Accrued expense and other current liabilities Cash used in operating activities from continuing operations Net cash used in operating activities from discontinued operations Net cash used in operating activities Cash flows from investing activities: Short-term deposit Purchase of property and equipment Cash used in investing activities from continuing operations Cash used in investing activities from discontinued operations Cash used in investing activities Cash flows from financing activities: Proceeds from issuance of convertible securities (of which $0 and $50 are with related parties in 2026 and 2025, respectively) Payments in connection with initial public offering costs Proceeds from issuance of Ordinary Shares and Ordinary Warrants in a private placement, net Net cash provided by financing activities Cash used in financing activities from discontinued operations Net cash provided by financing activities Effect of exchange rate changes on cash, cash equivalents and restricted cash Net increase (decrease) in cash and cash equivalents Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental disclosure of non-cash financing activities: Offering cost included in accrued expense and other current liabilities Cash and cash equivalents Restricted cash Cash, cash equivalents and restricted cash at end of period Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND NATURE OF THE BUSINESS Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Debt Disclosure [Abstract] FAIR VALUE MEASUREMENTS Commitments and Contingencies Disclosure [Abstract] CONTINGENT LIABILITIES AND COMMITMENTS Segment Reporting [Abstract] SEGEMENT REPORTING Earnings Per Share [Abstract] NET LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDER Related Party Transactions [Abstract] RELATED PARTIES Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATIONS OTHER SIGNIFICANT EVENTS DURING THE PERIOD Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation Use of estimates Recently Adopted Accounting Standards Recently Issued Accounting Standards Not Yet Adopted SCHEDULE OF SIGNIFICANT INPUTS IN MEASURING SCHEDULE OF LEVEL 3 FINANCIAL LIABILITIES Segment Reporting [Table] Segment Reporting [Line Items] SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES REGULARLY REVIEWED BY THE CODM SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET LOSS PER SHARE SCHEDULE OF DILUTED NET LOSS PER SHARE ANTI-DILUTIVE Related Party Transaction [Table] Related Party Transaction [Line Items] SCHEDULE OF RELATED PARTY BALANCES INCLUDED IN BALANCE SHEETS SCHEDULE OF RELATED PARTY TRANSACTION INCLUDED IN STATEMENTS OF OPERATIONS SCHEDULE OF DISCONTINUED OPERATIONS Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Net loss Income loss from continuing operations Net cash flows from operations Net cash used in continuing operations Retained earnings accumulated deficit Gross proceeds from the IPO Shareholders, share split Sale of stock, shares issued Sale of stock, price per share Underwriting discounts and commissions Warrants to purchase Warrants to purchase Issuance costs Proceeds from issuance of private placement Agent fees Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Fair value of Ordinary Share SAFEs measurement input Time to maturity Begining balance Begining balance Begining balance Begining balance Debt Conversion, Converted Instrument, Amount Proceeds from Convertible Debt Stock Issued During Period, Value, New Issues Conversion of stock, shares converted Legal proceedings amount Litigation settlement Royalties percentage Payments for royalties Commitments term Termination amount Periodic payments Research and Development Expense Development services, additional fees Amount paid, service Proceeds from Sale of Other Productive Assets Paid to other breach Outstanding payable Accounts payable and other current and noncurrent Termination fees Payment amount Payment amount Payment of instalments New Aptar Agreement Additional milestone payments Prepaid expense Payroll and payroll related Subcontractors and consultants Professional services Other Loss (income) from change in fair value of convertible securities Interest income Other expense, net Deferred issuance costs Net loss (income) from discontinued operations Number of operating segment Number of reportable segment Loss from continuing operations Net loss (income) from discontinued operations Net loss attributable to holders of Ordinary Shares Loss from continuing operations Net loss (income) from discontinued operations Net loss attributable to holders of Ordinary Shares and assumed conversions Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Net income (loss) per share, basic: Continuing operations Discontinued operations Net loss per share, basic Net income (loss) per share, diluted: Continuing operations Discontinued operations Net loss per share, diluted Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] 2024 SAFE CURRENT LIABILITIES: Trade payables Ordinary shares issued and outstanding, percentage Management fee description Management fee Voluntary fee Deferred fees Deferred liability Compensation adjustments description Management fee Proceeds from private placement Bonus rate Monthly rent fee Secretarial services fee Secretarial services fee increased Investments Short term investments Related party transaction, description Transaction costs Management received a bonus Bonus received for subject to shareholder approval Other income (expense), net Net income (loss) from discontinued operations Liabilities Current Liabilities: Accounts payable Accrued expense and other current liabilities Advances from customers Current liabilities related to discontinued operations CommitmentsAndContingenciesTable [Table] CommitmentsAndContingenciesLineItems [Line Items] Other commitments description Shares option grants Number of shares issued Share price Conversion of stock description Common stock shares authorized Authorized Share Capital Number of shares options Share options, excercise price Milestone bonus Subsequent Event [Table] Subsequent Event [Line Items] Annual bonus Annual base salary Stock options granted Vesting percentage Change in fair value of convertible securities. License Agreement [Member] Commitments term. Change in fair value of convertible securities. Effect of exchange rates. Short term deposit. Offering cost included in accrued expense and other current liabilities. Termination amount. Increase decrease in noncash lease expense. Service Agreement [Member] Services Agreement [Member] Non Recurring Research Arrangement [Member] Aptar Technology [Member] Liability termination fees. Nasus Pharmas Intranasal Naloxone Powder Spray [Member] Nasus Pharmas Intranasal Epinephrine Powder Candidate [Member] Settlement Agreement [Member] Payments for final settlement. New Master Service Agreement [Member] Milestone payments. Additional milestone payments. New Aptar Agreement [Member] Consulting Agreement [Member] Payroll and payroll related expenses. Subcontractors and consultants expenses. Loss income from change in fair value of convertible securities. Net loss per share, basic. Net loss per share, diluted. 2024 SAFE [Member] Underwriter Warrants [Member] Ordinary Warrants [Member] Ordinary shares issued and outstanding percentage. Dr. Dalia Meggido [Member] Mr Udi Gilboa [Member] Dr Ronnie Hershman [Member] Mr. Ehud Gilboa and Dr. Dalia Meggido [Member] Mr. Ehud Gilboa [Member] Payment for deferred fees. Bonus rate. Udi Gilboa [Member] Underwriting Agreement [Member] Securities Purchase Agreement [Member] Agent fees. 2024 SAFEs [Member] Management received bonus. Bonus received for subject to shareholder approval. Recently Issued Accounting Standards Not Yet Adopted [Policy Text Block] Disposal group including discontinued operation other income expense. Income loss from discontinued operation net of tax attributable to reporting entity. Disposal group including discontinued operation advances from customers. Weight Average Cost Capital [Member] Fair value measurement with unobservable inputs reconciliation recurring basis liability change in period increase decrease. 2019 Plan [Member] Sub Plan [Member] Proceeds from annual bonus. Mr.Dan Teleman [Member] Deferred issuance costs. Single Reportable Segment [Member] Share Options [Member] Royalties percentage. Supply Agreement [Member] Non-executive Directors [Member] Assets, Current Assets Liabilities, Current Liabilities [Default Label] Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) ChangeInFairValueOfConvertibleSecurities Earnings Per Share, Basic Earnings Per Share, Diluted Shares, Outstanding Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Cash Provided by (Used in) Operating Activity, Continuing Operation Cash Provided by (Used in) Operating Activity, Including Discontinued Operation ShortTermDeposit Payments to Acquire Property, Plant, and Equipment Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Payments of Debt Issuance Costs Cash Provided by (Used in) Financing Activity, Continuing Operation Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Other Item Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInPeriodIncreaseDecrease PaymentsForFinalSettlement Interest Income (Expense), Nonoperating DeferredIssuanceCosts Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Net Income (Loss) Available to Common Stockholders, Basic Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Diluted Net Income (Loss) Available to Common Stockholders, Diluted Income (Loss) from Continuing Operations, Per Diluted Share Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Management Fee Expense IncomeLossFromDiscontinuedOperationNetOfTaxAttributableToReportingEntity Disposal Group, Including Discontinued Operation, Accounts Payable, Current Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current